Long-Term Satisfaction and Tolerability with Low-Dose Flutamide: A 20-Year Surveillance Study on 120 Hyperandrogenic Women

May 2016 in “ Gynecological Endocrinology ”

Camil Castelo-Branco, Claudio Hernández-Angeles, Lina Alvarez-Olivares, Juan Balasch

flutamide hirsutism hyperandrogenic dry skin hypertransaminasemia acute fatty liver

Studysummary This study found that while flutamide was very effective in improving hirsutism in women over long-term treatment, a high incidence of adverse effects led to a majority discontinuing the therapy.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on tandfonline.com →

Discuss this study in the Community →

Research cited in this study

8 / 8 results

research Interventions for Hirsutism

6 citations , November 2015 in “JAMA”

This study found that oral contraceptive pills improve mild hirsutism, while flutamide and spironolactone are beneficial for more severe cases, but other therapies show inconsistent or no benefit.

American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1

research American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1

343 citations , October 2015 in “Endocrine Practice”

This review discusses the diagnostic criteria and management strategies for Polycystic Ovary Syndrome (PCOS) and highlights the need for comprehensive clinical assessment, but does not report new clinical findings.

research Hepatotoxicity with Low- and Ultralow-Dose Flutamide: A Surveillance Study on 203 Hyperandrogenic Young Females

29 citations , July 2012 in “Fertility and Sterility”

This study observed that hepatotoxicity is a rare but possible event in hyperandrogenic young females treated with low- and ultralow-dose flutamide, regardless of dose or oral contraceptive use.

research Prospective Cohort Study on the Effects and Tolerability of Flutamide in Patients with Female Pattern Hair Loss

42 citations , April 2011 in “Annals of Pharmacotherapy”

This study found that long-term flutamide treatment reduced hair loss in women with female pattern hair loss, but liver-related dropouts were minimized at a very low dose of 62.5 mg/day.

research Comprehensive Clinical Management of Hirsutism

14 citations , March 2010 in “Gynecological endocrinology”

This article provides an overview of treatment options for hirsutism, summarizing both pharmacologic and non-pharmacologic approaches, but reports no new clinical results.

research Androgen Dependence of Hirsutism, Acne, and Alopecia in Women

105 citations , January 2009 in “Medicine”

This study found that ethinylestradiol and high-dose cyproterone acetate significantly reduced hirsutism scores and were effective for treating acne and alopecia in women with hyperandrogenism.

research Hirsutism and Acne in Polycystic Ovary Syndrome

169 citations , August 2004 in “Baillière's best practice & research. Clinical obstetrics & gynaecology/Baillière's best practice and research in clinical obstetrics and gynaecology”

This article discusses treatments for hirsutism and acne in women with polycystic ovary syndrome, suggesting that lower doses of current medications maintain efficacy while reducing cost and side effects, but reports no new clinical results.

research Relative Safety and Efficacy of Finasteride for Treatment of Hirsutism

29 citations , April 2004 in “Annals of Pharmacotherapy”

This review concluded that finasteride may reduce hirsutism scores and hair diameter in women with hyperandrogenism, but concerns about teratogenicity and long-term safety make it a secondary treatment option.